Literature DB >> 9029078

Plasma levels of amyloid beta proteins Abeta1-40 and Abeta1-42(43) are elevated in Down's syndrome.

T Tokuda1, T Fukushima, S Ikeda, Y Sekijima, S Shoji, N Yanagisawa, A Tamaoka.   

Abstract

To investigate the effect of the overexpression of beta-amyloid precursor protein (APP) on the production of two major amyloid beta protein (Abeta) species, Abeta40 and Abeta42(43), we measured amounts of Abeta1-40 and Abeta1-42(43) in the plasma from 44 patients with Down's syndrome (DS) (age, 19-61 years) and 66 age-matched normal controls using enzyme-linked immunosorbent assays. Plasma concentrations of both Abeta1-40 and Abeta1-42(43) were increased about 3-fold and 2-fold, respectively, in DS patients compared with normal controls. Especially, the increases in plasma Abeta1-40 in DS patients were statistically higher than the 1.5-fold increase one might predict based on the gene dose of APP in DS. These findings showed that both Abeta1-40 and Abeta1-42(43) are increased in plasma in DS patients, the former more than the latter, suggesting that overexpression of APP and/or other genes may have different effects on the production of these two Abeta species in DS.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9029078     DOI: 10.1002/ana.410410220

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  29 in total

1.  A notable cleavage: winding up with beta-amyloid.

Authors:  K S Kosik
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

2.  Change in plasma Aß peptides and onset of dementia in adults with Down syndrome.

Authors:  N Schupf; W B Zigman; M-X Tang; D Pang; R Mayeux; P Mehta; W Silverman
Journal:  Neurology       Date:  2010-11-02       Impact factor: 9.910

3.  Problems associated with biological markers of Alzheimer's disease.

Authors:  H J Frey; K M Mattila; M A Korolainen; T Pirttilä
Journal:  Neurochem Res       Date:  2005-12       Impact factor: 3.996

4.  Dissociation between the processivity and total activity of γ-secretase: implications for the mechanism of Alzheimer's disease-causing presenilin mutations.

Authors:  Omar Quintero-Monzon; Morgan M Martin; Marty A Fernandez; Christina A Cappello; Amanda J Krzysiak; Pamela Osenkowski; Michael S Wolfe
Journal:  Biochemistry       Date:  2011-09-30       Impact factor: 3.162

Review 5.  The Ubiquitin-Proteasome System and Molecular Chaperone Deregulation in Alzheimer's Disease.

Authors:  Yanuar Alan Sulistio; Klaus Heese
Journal:  Mol Neurobiol       Date:  2015-01-07       Impact factor: 5.590

Review 6.  Alzheimer's disease.

Authors:  Dennis J Selkoe
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-07-01       Impact factor: 10.005

7.  Down Syndrome, Partial Trisomy 21, and Absence of Alzheimer's Disease: The Role of APP.

Authors:  Eric Doran; David Keator; Elizabeth Head; Michael J Phelan; Ron Kim; Minodora Totoiu; Jorge R Barrio; Gary W Small; Steven G Potkin; Ira T Lott
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

8.  Plasma amyloid-β as a function of age, level of intellectual disability, and presence of dementia in Down syndrome.

Authors:  Elizabeth Head; Eric Doran; Mihaela Nistor; MaryAnn Hill; Frederick A Schmitt; Richard J Haier; Ira T Lott
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

9.  Plasma beta-amyloid and duration of Alzheimer's disease in adults with Down syndrome.

Authors:  V P Prasher; S G Sajith; P Mehta; W B Zigman; N Schupf
Journal:  Int J Geriatr Psychiatry       Date:  2010-02       Impact factor: 3.485

Review 10.  Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology.

Authors:  Elizabeth Head; Ira T Lott; Donna M Wilcock; Cynthia A Lemere
Journal:  Curr Alzheimer Res       Date:  2016       Impact factor: 3.498

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.